|
|
 |
December 11, 2007 |
Now Available: Download the podcast of Dr. Burke's video presentation
Musculoskeletal Report provides cutting-edge scientific updates through in-depth interviews, on-location coverage of medical meetings, expert-led panel discussions, and live newscasts. With biweekly and special edition newsletters, MSK Report is the top online resource for staying abreast of the most current and clinically relevant information in the field of musculoskeletal disease and treatment.
MSK Video Report:
Treating Osteoporosis in the New Era: Examining the Function and Structure of Bone
Susan Burke, MD discusses new developments in the identification, prevention and treatment of osteoporosis...
Autoimmunity: Identification of Two New Ankylosing Genes Suggest Novel Therapeutic Targets
Genome scans have identified two of the suspected handful of non-MHC genes that appear to collaborate with HLA-B27 in "turning on" disease processes that result in ankylosing spondylitis and other seronegative arthropathies...
Bones: Doctors Rally to Save DXA from Medicare Cuts
If proposed Medicare cuts that would drastically reduce access to dual X-ray absorptiometry (DXA) are approved, many physicians will be unable able to offer DXA services in their offices and undetected osteoporotic fracture rates are likely to climb, healthcare researchers predict...
BioPharm Business: Pfizer, Adolor Enter Into Exclusive Worldwide Collaboration to Develop and Commercialize Delta Opioid Receptor Agonists to Treat Range of Inflammatory, Neuropathic, and Acute Pain
Pfizer Inc and Adolor Corp, a leader in the area of novel, opioid receptor-targeted therapeutics, announced an exclusive worldwide collaboration to develop and commercialize delta opioid receptor agonist candidates, ADL5859 and ADL5747, for the treatment of pain...
BioPharm Business: Pain Therapeutics', King's Remoxy Meets Primary Endpoint in Pivotal Phase III Study in OA Patients with Chronic Pain; NDA Filing Expected in Mid-2008
Pain Therapeutics, Inc and King Pharmaceuticals, Inc announced that a pivotal phase III study of Remoxy, an abuse-deterrent version of long-acting oxycodone, in osteoarthritis patients with chronic pain met the primary endpoint that was prospectively defined by the US FDA during the Special Protocol Assessment process...